|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter hypermethylation was detected in 38.7% of glioblastoma patients.
|
31701343 |
2020 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The CpG methylation status of the MGMT promoter strongly correlates with clinical outcome and, therefore, is used as prognostic marker during glioblastoma therapy.
|
31395346 |
2020 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here, we quantify baseline expression of MGMT and EGFR protein in newly diagnosed GBM samples using mass spectrometry.
|
31823165 |
2020 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The results confirm that the quantitative level of MGMT promoter methylation is a positive prognostic factor in newly diagnosed patients with GBM.
|
31422371 |
2020 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Histological examination confirmed a wild-type (WT) IDH1/2, MGMT (DNA repair enzyme O6-methylguanine-DNA methyltransferase) methylated glioblastoma with a proliferative index focally as high as 20%.
|
31173153 |
2020 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT methylation appears to convey a survival benefit in the setting of bevacizumab treatment for progressive GBM.
|
31756059 |
2020 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients.
|
31784096 |
2020 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
• ASL-PWI can aid to predict IDH and MGMT promoter methylation statuses in GBM.
|
31468161 |
2020 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Combined Therapy Sensitivity Index Based on a 13-Gene Signature Predicts Prognosis for IDH Wild-type and MGMT Promoter Unmethylated Glioblastoma Patients.
|
31632497 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MGMT is one of the important markers in glioblastomas as it not only predicts response to therapy but may also be used as an independent prognostic marker.
|
30444735 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Epigallocatechin Gallate Preferentially Inhibits O<sup>6</sup>-Methylguanine DNA-Methyltransferase Expression in Glioblastoma Cells Rather than in Nontumor Glial Cells.
|
30558449 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overexpression of macrophage migration inhibitory factor (MIF) was identified in human GBM specimens that were MGMT methylated but showed poor survival.
|
30814573 |
2019 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The standard deviation (SD) of rCBV was significantly higher in glioblastoma (GBM) with methylated O6-methylguanine DNA methyltransferase (MGMT; 1.99 ± 0.73; p = 0.001) than in those with unmethylated MGMT (1.20 ± 0.45).
|
29468261 |
2019 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
The frequency of MGMT promoter methylation in GBMs was 49.2%, which was significantly associated with IDHR132H mutation and ATRX loss.
|
30038102 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Four hundred and fifty one (45.9%) GBM biopsies were positive MGMT PM.
|
30500933 |
2019 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Clinical data (age, sex, extent of surgical resection), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and pre-operative T2WI of 113 pathologically confirmed glioblastoma patients (from our institution, n = 61; from the Cancer Imaging Archive, n = 52) were retrospectively reviewed.
|
31150499 |
2019 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Although the two classical molecular markers of glioblastoma including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation are associated with overall survival rate of glioblastoma patients, they are not specific to the survival outliers.
|
31159876 |
2019 |
|
Glioblastoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We discovered that RARRES1 is highly expressed in patients with mesenchymal subtype, unmethylated MGMT, IDH1 wild type, and non-G-CIMP, all of which are molecular characteristics of malignant GBM.
|
31632537 |
2019 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
TMZ-naïve hypermutated tumors were marked by absence of IDH1 somatic mutation and MGMT promoter (pMGMT) methylation, two genomic traits that were significantly associated with the TMZ-induced hypermutagenic event in glioblastoma, and harbored inherited alterations in the mismatch repair (MMR) machinery.
|
30536544 |
2019 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
We have assessed MGMT methylation status in blood and tissue samples from unresected glioblastoma patients who had been included in the randomized GENOM-009 trial.
|
31366977 |
2019 |
|
Glioblastoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We showed that ionizing radiation and temozolomide reduced the viability of cancer stem cells from GBM patients, as well as modified MGMT gene and miRNA-181d expression in cancer stem cells, suggesting that miRNA-181d interferes in the glioblastoma cancer stem cell response to treatment with temozolomide and ionizing radiation.
|
31226325 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Patients with glioblastoma without O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with temozolomide (TMZ).
|
30277538 |
2019 |
|
Glioblastoma
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Surprisingly, integrative analyses demonstrated that O6-methylguanine-DNA methyltransferase methylation and isocitrate dehydrogenase mutation status were equally distributed among glioblastoma metabolic profiles.
|
30476237 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
LC-MS/MS plasma stability assays were conducted in mice to further explore the stability profile of TMZ@Calix <i>in vivo</i> The therapeutic efficacy of TMZ@Calix was compared with that of unbound TMZ in GBM cell lines and patient-derived primary cells with known O6-methylguanine-DNA methyltransferase (<i>MGMT</i>) expression status and <i>in vivo</i> in an intracranial U87 xenograft mouse model.
|
31213505 |
2019 |
|
Glioblastoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.
|
31058280 |
2019 |